Annual CFO
-$23.03 M
+$10.43 M+31.18%
31 December 2022
Summary:
Zynerba Pharmaceuticals annual cash flow from operations is currently -$23.03 million, with the most recent change of +$10.43 million (+31.18%) on 31 December 2022. During the last 3 years, it has risen by +$18.29 million (+44.26%).ZYNE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$8.42 M
-$537.40 K-6.82%
30 June 2023
Summary:
Zynerba Pharmaceuticals quarterly cash flow from operations is currently -$8.42 million, with the most recent change of -$537.40 thousand (-6.82%) on 30 June 2023.ZYNE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$31.64 M
-$534.10 K-1.72%
30 June 2023
Summary:
Zynerba Pharmaceuticals TTM cash flow from operations is currently -$31.64 million, with the most recent change of -$534.10 thousand (-1.72%) on 30 June 2023.ZYNE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +44.3% | +16.2% | +3.0% |
| 5 y5 years | +28.9% | +23.4% | +5.7% |
ZYNE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | >+9999.0% | -4296.3% | >+9999.0% |
Zynerba Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$8.42 M(+6.8%) | -$31.64 M(+1.7%) |
| Mar 2023 | - | -$7.88 M(+38.6%) | -$31.11 M(+35.1%) |
| Dec 2022 | -$23.03 M(-31.2%) | -$5.69 M(-41.1%) | -$23.03 M(-8.5%) |
| Sept 2022 | - | -$9.66 M(+22.5%) | -$25.18 M(-1.5%) |
| June 2022 | - | -$7.88 M(-4030.0%) | -$25.56 M(+2.4%) |
| Mar 2022 | - | $200.60 K(-102.6%) | -$24.96 M(-25.4%) |
| Dec 2021 | -$33.46 M(-19.0%) | -$7.83 M(-22.0%) | -$33.46 M(+2.6%) |
| Sept 2021 | - | -$10.05 M(+37.9%) | -$32.61 M(-7.4%) |
| June 2021 | - | -$7.28 M(-12.2%) | -$35.23 M(-8.7%) |
| Mar 2021 | - | -$8.29 M(+18.7%) | -$38.61 M(-6.5%) |
| Dec 2020 | -$41.31 M(+18.7%) | -$6.99 M(-44.8%) | -$41.31 M(-1.1%) |
| Sept 2020 | - | -$12.67 M(+18.8%) | -$41.79 M(+4.2%) |
| June 2020 | - | -$10.66 M(-3.1%) | -$40.11 M(+10.5%) |
| Mar 2020 | - | -$11.00 M(+47.3%) | -$36.30 M(+4.2%) |
| Dec 2019 | -$34.82 M(+7.5%) | -$7.46 M(-32.0%) | -$34.82 M(+3.7%) |
| Sept 2019 | - | -$10.98 M(+60.4%) | -$33.56 M(+13.8%) |
| June 2019 | - | -$6.85 M(-28.1%) | -$29.49 M(-6.6%) |
| Mar 2019 | - | -$9.52 M(+53.4%) | -$31.56 M(-2.6%) |
| Dec 2018 | -$32.40 M | -$6.21 M(-10.2%) | -$32.40 M(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$6.91 M(-22.5%) | -$32.90 M(+10.4%) |
| June 2018 | - | -$8.92 M(-13.9%) | -$29.80 M(+4.4%) |
| Mar 2018 | - | -$10.36 M(+54.3%) | -$28.55 M(+10.5%) |
| Dec 2017 | -$25.84 M(+26.4%) | -$6.71 M(+76.3%) | -$25.84 M(+4.9%) |
| Sept 2017 | - | -$3.81 M(-50.4%) | -$24.64 M(-6.7%) |
| June 2017 | - | -$7.67 M(+0.3%) | -$26.41 M(+12.8%) |
| Mar 2017 | - | -$7.65 M(+38.9%) | -$23.41 M(+14.6%) |
| Dec 2016 | -$20.44 M(+108.8%) | -$5.51 M(-1.3%) | -$20.44 M(+12.8%) |
| Sept 2016 | - | -$5.58 M(+19.3%) | -$18.13 M(+15.8%) |
| June 2016 | - | -$4.68 M(+0.0%) | -$15.65 M(+24.7%) |
| Mar 2016 | - | -$4.67 M(+46.4%) | -$12.55 M(+28.2%) |
| Dec 2015 | -$9.79 M(+176.4%) | -$3.19 M(+2.9%) | -$9.79 M(+21.4%) |
| Sept 2015 | - | -$3.10 M(+97.4%) | -$8.06 M(+26.3%) |
| June 2015 | - | -$1.57 M(-17.9%) | -$6.38 M(+23.4%) |
| Mar 2015 | - | -$1.92 M(+30.6%) | -$5.17 M(+46.0%) |
| Dec 2014 | -$3.54 M(+2908.2%) | -$1.47 M(+2.9%) | -$3.54 M(+70.7%) |
| Sept 2014 | - | -$1.42 M(+292.1%) | -$2.07 M(+219.0%) |
| June 2014 | - | -$363.20 K(+26.6%) | -$650.20 K(+126.6%) |
| Mar 2014 | - | -$287.00 K | -$287.00 K |
| Dec 2013 | -$117.70 K | - | - |
FAQ
- What is Zynerba Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Zynerba Pharmaceuticals?
What is Zynerba Pharmaceuticals annual cash flow from operations?
The current annual CFO of ZYNE is -$23.03 M
What is the all time high annual CFO for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high annual cash flow from operations is -$117.70 K
What is Zynerba Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ZYNE is -$8.42 M
What is the all time high quarterly CFO for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high quarterly cash flow from operations is $200.60 K
What is Zynerba Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ZYNE is -$31.64 M
What is the all time high TTM CFO for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high TTM cash flow from operations is -$287.00 K